China passes U.S. in Surgical Procedures in 2019 for first time in history.

Posted by Life Science Intelligence on Oct 21, 2019 7:17:52 AM
Find me on:

Healthcare in China is in a constant state of reform as the system evolves to meet the unique burdens of the country which rapidly became the world’s second largest economy. With a population of approximately 1.4 billion people, demand for healthcare services is at an all-time high in China, with many hospitals understaffed and overwhelmed by demand.

The elderly demographic continues to increase in China. Approximately 11% of the population is over the age of 65, which translates to approximately 154 million people. It is well noted that personal healthcare expenditure continues to rise with age as the risk of developing chronic conditions is heavily correlated with an individual’s age. As a result of this growing elderly demographic, surgical procedure volumes in China are projected to rapidly increase. Indeed, many types of surgical procedures are projected to increase at a CAGR between 10% and 15% from 2019 to 2022.

According to 2019 estimates from LSI’s Global Procedure Volume Tracker, the top three procedure categories, by total procedure volume, in China will be:

  • Obstetrical and gynecological procedures – 29.7 million procedures. These were primarily attributable to destructive operations.

  • Urological procedures – 20.5 million procedures. BPH surgeries accounted for the largest share of urological surgical procedures, which can in part be attributed to the gender imbalance in China.

  • General surgical procedures – 6.5 million procedures. These procedures are split fairly evenly across various endoscopic and laparoscopic procedures.

China_US SVP_LinkedIn

General surgical procedures and urological procedures were also among the top procedure categories for the US, although overall demand was reversed (general surgical procedures outpaced urological procedures in the US). Government population control policies in China are the reason for the significant number of destructive operations performed in China each year.

The rapid growth in surgical procedures in the near future is a reason why medtech companies have strived to penetrate the Chinese market. Despite this rapid growth, there are problems on the horizon for the Chinese healthcare system. There are still substantial issues with access and quality of healthcare in China. These issues are primarily attributed to urban vs. rural factors, income inequality, and an inability to meet the demand for healthcare. While great strides have been made to improve the affordability of healthcare in China, there is a tipping point in the future should the Chinese government be unable to find a solution to the shortage of healthcare specialists needed to provide care to such a large population.

Long-term, it is unlikely that the growth in surgical procedure volumes can be sustained. China is a graying nation, with an estimated birth rate of 1.62 births per woman as of 2016 – a rate considered to be below population replacement level. Researchers believe that by 2030, the population of China will begin an “unstoppable” decline which will have serious economic repercussions for the country. Further complicating the issue are the future economic concerns facing the country, with much of the population growing old before achieving middle-income status. This will make it difficult for many people to access healthcare that they will certainly require in the advanced years of their life.

LSI’s Global Procedure Volume Tracker projects procedure volume growth for over 200 procedures, offering country-specific and global insights on trends in surgical procedures. Surgical procedure volume growth shows no signs of slowing down, with newer interventions such as stereotactic radiosurgery and minimally invasive heart valve replacement surgery seeing rapid adoption across all major regions.

The next installment in this series will look at surgical procedure volume trends in the five major European countries – France, Germany, Italy, Spain, and the United Kingdom.

Learn more about PV Tracker and the Medtech Pro platform at: www.lifesciencemarketresearch.com

 

Topics: Insider, Medtech, Surgical Procedure Volumes

Stay connected with our latest posts:

About the Author

Life Science Intelligence (LSI) helps medtech executives make better strategic decisions by delivering unique market data and business insights. For over 13 years LSI has been working with industry giants – Johnson & Johnson, Medtronic, Abbott, Stryker, Cardinal, Boston Scientific, and Becton Dickinson, among others. LSI products are also leveraged by the most successful start-ups, innovators, investors, and service companies that compete in medtech. LSI is the organizer of The Emerging Medtech Summit held annually in Southern California.

Contact LSI here, via phone 714 847 3540, or email info@lsintel.com